Home > Insider Trading > Filing (0000950170-24-002278)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818794	Dyne Therapeutics Inc.	DYN	Pharmaceutical Preparations (2834)	364883909

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1824673	Jonathan Mcneill	1560 Trapelo Road Waltham MA 02451	Chief Business Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-01-02	11,900	$13.10	143,618	No	4	S	Direct
Common Stock	Acquisiton	2024-01-03	17,991	$0.73	161,609	No	4	M	Direct
Common Stock	Disposition	2024-01-03	7,691	$18.34	153,918	No	4	S	Direct
Common Stock	Disposition	2024-01-03	10,300	$19.03	143,618	No	4	S	Direct
Common Stock	Acquisiton	2024-01-04	2,009	$0.73	145,627	No	4	M	Direct
Common Stock	Disposition	2024-01-04	2,009	$18.04	143,618	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2024-01-03	17,991	$0.00	17,991	$0.73
Common Stock	Stock option (right to buy)	Disposition	2024-01-04	2,009	$0.00	2,009	$0.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
50,537		2029-02-25	No	4	M	Direct
48,528		2029-02-25	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.76 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
Includes 143,067 unvested RSUs.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.07, inclusive.
The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter.